DENVER(EGMN) –A novel oral, once-daily, tissue-selective estrogen complex designed to treat postmenopausal symptoms more safely than traditional estrogen/progestin hormone therapy achieved an overall favorable effect on metabolic parameters in a large phase III clinical trial.
The combination of the selective estrogen receptor modulator (SERM) bazedoxifene and conjugated estrogens produced “very favorable” changes in lipid profiles and no clinically meaningful effects on coagulation parameters, fibrinolytic activity, or carbohydrate metabolism in the phase III SMART-1 trial, Dr. Hugh S. Taylor reported at the annual meeting of the American Society for Reproductive Medicine.
The concept underlying the tissue-selective estrogen complex (TSEC) is that the SERM will serve as an antagonist to estrogen’s adverse effects on the uterus and breast without interfering with its favorable CNS effects on vasomotor symptoms, explained Dr. Taylor of Yale University, New Haven, Connecticut.
The Selective Estrogens, Menopause, and Response to Therapy (SMART-1) trial was a 2-year, double-blind, multicenter, placebo- and active comparator-controlled study involving 7,492 postmenopausal women aged 40-72 years with an intact uterus and acceptable baseline endometrial biopsy results. They were randomized to one of eight treatment arms: bazedoxifene at 10, 20, or 40 mg, each combined with conjugated estrogens at 0.45 or 0.625 mg; raloxifene at 60 mg/day; or placebo.
There are three large randomized SMART trials in the bazedoxifene/conjugated estrogens development program. Prior reports from SMART-1 showed that the TSEC significantly increased bone mineral density while reducing hot flashes and vulvar/vaginal symptoms compared with placebo (Fertil. Steril. 2009;92:1025-38,1045-52). TSEC also was associated with low rates of endometrial hyperplasia and cumulative amenorrhea rates comparable to those with placebo (Fertil. Steril. 2009;92:1018-24,1039-44). In the overall SMART series, the thrombotic event rate in TSEC-treated patients was similar to that of estrogen alone. In other words, there was no synergistic effect on clotting events with the combined therapy. The TSEC had no effect on blood pressure, Dr. Taylor continued.
At the meeting, he presented for the first time the results of the SMART-1 metabolic substudy. Metabolic end points take on particular importance because menopause is often associated with unfavorable effects on the metabolic profile. Dr. Taylor focused on the subset of women treated with bazedoxifene 20 mg/conjugated estrogens 0.45 mg because that’s the regimen going forward in development under the trade name Aprela.
The metabolic substudy included 111 women randomized to Aprela and 108 on placebo. All were 1-5 years postmenopausal, with an average of 3 years since their last menstrual period.
Patients who took Aprela had a mean 11% reduction in LDL cholesterol over a 2-year period compared with baseline, a significantly greater change than with placebo. Other significant lipid changes in the Aprela group included a 4% decrease in total cholesterol, an 11% increase in HDL cholesterol level, a 28% rise in the cardioprotective HDL2 subfraction, an 11% increase in apolipoprotein A-I, and a 19% drop in lipoprotein (a). Most of these favorable changes were significantly greater than with placebo at all time points in the study, with testing done at 6, 12, 18, and 24 months.
The fly in the lipid ointment was the 23% increase in triglyceride levels in the Aprela group, which was significantly greater than the 6% increase in the placebo arm. Most hormonal therapies have this unwelcome effect of boosting triglycerides, Dr. Taylor observed.
In terms of coagulation parameters, the Aprela group showed favorable changes in fibrinogen, antithrombin III activity, and plasminogen activator inhibitor–1 activity that were statistically significantly greater than with placebo, but small in size and not clinically meaningful. Fasting insulin, fasting glucose, plasma homocysteine, C-reactive protein, and thyroid-stimulating hormone levels were unaffected by Aprela, he said.
The SMART-1 trial was funded by Wyeth, which has been acquired by Pfizer Inc. Dr. Taylor declared that he has received research grants from and has been on the speakers bureau for the companies.
Copyright (c) 2010 Elsevier Global Medical News. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
丹佛 (EGMN)——一项大型的Ⅲ期临床试验结果显示，一种每日口服的组织选择性复合雌激素与传统的雌/孕激素治疗方法相比，在治疗妇女绝经后症状方面更为安全，在多种代谢指标中均获得满意的效果。
来自康涅狄格州纽黑文市耶鲁大学的Hugh S. Taylor博士在美国生殖医学学会年会上报告了其SMART-1(选择性雌激素、绝经和治疗反应研究)试验的研究成果。这项研究中所应用的药物为Aprela，含有巴多昔芬20 mg和结合雌激素0.45 mg。111名妇女被随机分至Aprela组，108名妇女被分至安慰剂组。所有参试者均绝经1~5年，平均绝经期为3年。
结果显示，联合应用选择性雌激素受体调节剂(SERM)巴多昔芬和结合雌激素可在脂类代谢方面获得满意的疗效，同时在凝血参数、纤溶活性或糖代谢方面没有具有临床意义的变化。
SMART-1研究由惠氏公司提供资金资助，惠氏公司已被辉瑞公司收购。研究者声明接受该公司的经济资助。
爱思唯尔 版权所有
